Recent Articles in News & Analysis

Biocytogen Pharma (Beijing) has granted an option for its B7H3/PTK7 BsADC to Ideaya Biosciences in an agreement worth up to $406 million. Biocytogen believes Ideaya’s DDR small molecules may be a good fit for its ADC candidate, a B7H3/PTK7 topo-I-payload BsADC program with first-in-class potential. B7H3/PTK7 is co-expressed in multiple solid tumors, including lung, colorectal, and head and neck cancers. Ideaya is a South San Francisco precision medicine oncology company that uses molecular diagnostics to identify patients for its targeted therapeutics. More details....

Stock Symbol: (HK: 02315)

Share this with colleagues:  

Suzhou Porton Advanced Solutions and Guangzhou Geneseed Biotech agreed to combine their circRNA gene therapy services and improve their offerings to CDMO clients. Porton Advanced will contribute its end-to-end cell and gene therapy CDMO service platform while Geneseed will add its core patented technologies in circRNA drug concept validation and process development. The two companies formed the collaboration to accelerate the development of novel circRNA therapies. More details....

Share this with colleagues:  

LTZ Therapeutics, a Shenzhen-Redwood City, CA immunotherapy biotech, completed a Series A financing of over $20 million. The company is developing Myeloid Engager candidates to enhance the phagocytic function of monocytes and macrophages. Using reverse translational science and new insights into the tumor microenvironment, LTZ’s novel immunotherapies are expected to overcome resistance and boost anti-tumor immunity. The A round was led by new investor Lapam Capital and includes GL Ventures, also a new investor. K2 Venture Partners and Shunwei Capital participated. So far, LTZ has raised $50 million since it was founded in 2022. More details....

Share this with colleagues:  

Shenzhen Synthetica Pioneering closed a Series A round to develop novel living bacterial therapeutics. Founded in 2023, the company specializes in genetic circuit engineering and precise control of genes and payloads to treat various diseases, especially solid tumor cancers. Synthetica is a spin-off from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences that uses synthetic biology techniques to engineer novel living bacterial therapeutics. The Series A funding was led by Boehringer Ingelheim Venture Fund and Temasek. The funding will be used to fast-track Synthetica's oncolytic bacterial candidates into clinical trials. More details....

Share this with colleagues:  

WuXi AppTec, a large China CRDMO, announced flat earnings for the first six months of 2024 despite, as the company said, “external challenges.” The external challenges are the BIOSECURE Act currently being considered by the US Congress, which aims to stop US biopharma companies from using WuXi as a drug development partner. During the first half of the year, WuXi’s revenues dropped by only 1.2% from the year earlier. Its US customers provided $1.5 billion (62%) of the company’s income, a small decline. More details....

Share this with colleagues: